A ‘real-world’ study of vaccinated healthcare workers has found Covishield and Covaxin could produce a high immune response in up to 95% recipients and prevent serious disease in those infected after immunisation. Interestingly, the Oxford vaccine Covishield could generate antibodies in more individuals compared to Bharat Biotech’s Covaxin, a pre-print of the first such Indian study has stated. Most vaccine efficacy studies so far have been lab-based.from India News | Latest News Headlines & Live Updates from India - Times of India https://ift.tt/3v1YGPv
0 Comments:
Post a Comment